Pontifax

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, founded in 2015. The company focuses on developing therapeutic drugs aimed at enhancing the effectiveness of anti-cancer therapies. Its lead product, LUT014, is a proprietary small molecule B-Raf inhibitor designed to facilitate the administration of epidermal growth factor receptor (EGFR) inhibitors. This innovative approach helps mitigate the common cutaneous side effects associated with EGFR treatments, thereby improving the overall quality of life for patients undergoing cancer therapy.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Raziel Health, established in 2012 and headquartered in Rehovot, Israel, is a pharmaceutical company with a dual focus. Firstly, it develops injectable treatments, notably RZL-012, a novel synthetic small molecule designed to reduce fat tissue by causing fat cell death at the injection site. This drug is currently in clinical trials for various fat tissue indications and aesthetics. Secondly, Raziel Health offers a patient monitoring platform that uses artificial intelligence and machine learning to support remote patient care, enabling healthcare providers to improve patient outcomes across a wide range of conditions. The company's mission is to provide world-class, affordable healthcare in the comfort of patients' homes.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel, specializing in the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product candidates include EB612, an oral formulation of parathyroid hormone currently in Phase II clinical trials for hypoparathyroidism, and EB613, which is also in Phase II trials for osteoporosis and under development for non-union fractures. Entera Bio employs proprietary delivery technology that protects large molecules and peptides in the gastrointestinal tract, making oral drug administration straightforward and user-friendly. The company has established a research collaboration and license agreement with Amgen Inc. to discover clinical candidates targeting inflammatory diseases and other serious conditions. Founded in 2009, Entera Bio is supported by a management team with over 50 years of combined experience in drug development.

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

EyeYon Medical Ltd. is an Israeli company specializing in the development of medical devices for the treatment of corneal edema. Founded by a team of experienced professionals in ophthalmology and business, the company is based in Jerusalem and operates within the Van Leer Technology Incubator. Its key products include Hyper-CL, a hyperosmotic contact lens that utilizes osmosis to extract fluids from corneal edema, thereby improving vision and alleviating pain. Additionally, EyeYon Medical offers DSPEK, an artificial endothelial layer designed to replace damaged endothelial tissue, which is crucial in cases of corneal edema. The company's innovative solutions are non-invasive, comfortable, and facilitate effective eye care for patients dealing with both acute and chronic ocular conditions.

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Isfiya, Israel, specializing in the development of a capsule-based system for colorectal cancer screening. The company's flagship product, C-Scan, employs low-dose X-rays to screen for polyps, masses, and colorectal cancers without the need for bowel preparation or invasive procedures. The C-Scan system comprises three components: the C-Scan Cap, an ingestible capsule that captures and transmits structural data; the C-Scan Track, a biocompatible device worn on the patient's back for tracking and data recording; and C-Scan View, software for processing and visualizing the collected clinical data. This innovative approach allows for the detection of clinically significant polyps with accuracy comparable to traditional colonoscopy while eliminating the need for retrieval of the capsule post-examination. Check-Cap aims to market its products in the United States, Europe, Israel, and Japan.

HeadSense Medical Ltd. is an early-stage company based in Netanya, Israel, focused on developing non-invasive diagnostic devices for brain health. Established in 2011, the company has created a validated and CE Mark approved intracranial pressure (ICP) monitor that is applicable in various medical fields, including neurosurgery, neurology, emergency medicine, and critical care. The device allows healthcare professionals to diagnose and monitor critical clinical parameters without the need for invasive procedures. In addition to its ICP monitor, HeadSense is actively working on expanding its product offerings to include diagnostic tools for cerebral vasospasm, concussion, and the quantification of traumatic brain injury severity, among others. The company operates in both the U.S. and Israel, aiming to enhance patient outcomes through innovative monitoring solutions.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

cCAM Biotherapeutics Ltd. is a clinical-stage company focused on the discovery and development of novel immunotherapies for cancer treatment. Founded in 2010 and based in Misgav, Israel, the company is advancing its lead candidate, CM-10, an immunomodulatory antibody designed to counteract the immunosuppressive effects of CEACAM1, a protein utilized by cancer cells. By inhibiting this protein, CM-10 aims to stimulate a cancer-specific immune response, targeting various malignancies such as melanoma, non-small-cell lung cancer, bladder cancer, gastric cancer, colorectal cancer, and ovarian cancer. cCAM Biotherapeutics is dedicated to developing innovative therapeutic solutions to improve outcomes for cancer patients.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, focused on developing innovative diagnostic and therapeutic drugs. Established in 1996, Aposense specializes in utilizing its patented platform technology to target apoptosis, or programmed cell death, which enables real-time imaging of disease activity and the development of targeted therapies. The company innovates in gene therapy by creating transport molecules that facilitate the introduction of genetic material, particularly small interfering RNA (siRNA), through biological membranes. Aposense is also known for its molecular nano-motors, which are designed to harness electrical properties of membranes for drug delivery, including its development of ATT-11T, a conjugate aimed at treating solid tumors.

Applied Immune Technologies Ltd. is involved in the development of therapeutic molecules aimed at treating cancer, viral infections, and autoimmune diseases. The company specializes in creating T-Cell Receptor-Like (TCRL) antibodies that target intracellular-derived peptides for various therapeutic and diagnostic purposes. These TCRL antibodies have applications in pathology, as well as in vaccine design, validation, and monitoring. Additionally, they are useful in analyzing antigen presentation in various diseases. Founded in 2006 and based in Haifa, Israel, the company was previously known as BioMimic Pharma and now operates as a subsidiary of Adicet Bio, Inc.

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, focused on developing innovative diagnostic and therapeutic drugs. Established in 1996, Aposense specializes in utilizing its patented platform technology to target apoptosis, or programmed cell death, which enables real-time imaging of disease activity and the development of targeted therapies. The company innovates in gene therapy by creating transport molecules that facilitate the introduction of genetic material, particularly small interfering RNA (siRNA), through biological membranes. Aposense is also known for its molecular nano-motors, which are designed to harness electrical properties of membranes for drug delivery, including its development of ATT-11T, a conjugate aimed at treating solid tumors.

CollPlant Biotechnologies Ltd. is a regenerative medicine company specializing in the 3D bioprinting of tissues and organs, as well as medical aesthetic products. Headquartered in Rehovot, Israel, the company utilizes its proprietary plant-based genetic engineering technology to produce recombinant human collagen (rhCollagen). CollPlant's product offerings include BioInks for tissue and organ bioprinting, a dermal filler for wrinkle treatment, 3D bioprinted breast implants, and the Vergenix line, which features a soft tissue repair matrix for tendinopathy and an advanced wound care product designed for various chronic wounds. Founded in 2004, CollPlant aims to address diverse needs in the fields of tissue repair and aesthetics across the United States, Canada, and Europe.

CollPlant Biotechnologies Ltd. is a regenerative medicine company specializing in the 3D bioprinting of tissues and organs, as well as medical aesthetic products. Headquartered in Rehovot, Israel, the company utilizes its proprietary plant-based genetic engineering technology to produce recombinant human collagen (rhCollagen). CollPlant's product offerings include BioInks for tissue and organ bioprinting, a dermal filler for wrinkle treatment, 3D bioprinted breast implants, and the Vergenix line, which features a soft tissue repair matrix for tendinopathy and an advanced wound care product designed for various chronic wounds. Founded in 2004, CollPlant aims to address diverse needs in the fields of tissue repair and aesthetics across the United States, Canada, and Europe.

CollPlant Biotechnologies Ltd. is a regenerative medicine company specializing in the 3D bioprinting of tissues and organs, as well as medical aesthetic products. Headquartered in Rehovot, Israel, the company utilizes its proprietary plant-based genetic engineering technology to produce recombinant human collagen (rhCollagen). CollPlant's product offerings include BioInks for tissue and organ bioprinting, a dermal filler for wrinkle treatment, 3D bioprinted breast implants, and the Vergenix line, which features a soft tissue repair matrix for tendinopathy and an advanced wound care product designed for various chronic wounds. Founded in 2004, CollPlant aims to address diverse needs in the fields of tissue repair and aesthetics across the United States, Canada, and Europe.

CollPlant Biotechnologies Ltd. is a regenerative medicine company specializing in the 3D bioprinting of tissues and organs, as well as medical aesthetic products. Headquartered in Rehovot, Israel, the company utilizes its proprietary plant-based genetic engineering technology to produce recombinant human collagen (rhCollagen). CollPlant's product offerings include BioInks for tissue and organ bioprinting, a dermal filler for wrinkle treatment, 3D bioprinted breast implants, and the Vergenix line, which features a soft tissue repair matrix for tendinopathy and an advanced wound care product designed for various chronic wounds. Founded in 2004, CollPlant aims to address diverse needs in the fields of tissue repair and aesthetics across the United States, Canada, and Europe.